MT-SP1 polynucleotides and polypeptides
US7227009B2 · kind B2 · utility
22Cited by
2References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2005 |
| Grant date | Jun 5, 2007 |
| Priority date | — |
| Expiry date | Oct 18, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.